| Trial ID: | L5295 |
| Source ID: | NCT00370942
|
| Associated Drug: |
Gw823093c A
|
| Title: |
GW823093C For The Treatment Of Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: GW823093C A|DRUG: GW823093C B|DRUG: GW823093C C
|
| Outcome Measures: |
Primary: Efficacy variables Dose response (change from baseline in HbA1c) at stipulated date in each treatment group, 12 weeks | Secondary: Long term safety variables, 64 weeks
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
159
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2006-04-01
|
| Completion Date: |
2006-11-25
|
| Results First Posted: |
|
| Last Update Posted: |
2018-08-31
|
| Locations: |
GSK Investigational Site, Hokkaido, 051-0005, Japan|GSK Investigational Site, Miyagi, 985-0852, Japan|GSK Investigational Site, Tokyo, 130-0004, Japan|GSK Investigational Site, Tokyo, 160-0017, Japan|GSK Investigational Site
|
| URL: |
https://clinicaltrials.gov/show/NCT00370942
|
